POET Technologies tumbles after announcing $150 million direct share offering

POET Technologies is tumbling in early trading Thursday after the optical communications company announced that it’s raising $150 million through the sale of about 20.7 million shares in a registered direct offering.

It’s an opportunity for management to cash in on the stock’s more than 30% rally year to date (as of Wednesday’s close).

“With a substantial base of cash, we plan to accelerate our pursuit of targeted acquisitions, add to our capabilities and talent base, vertically integrate our products with differentiated components, and expand operations to pursue revenue opportunities across the board, in order to bring long-term value to shareholders,” Executive Chairman and CEO Dr. Suresh Venkatesan said.

POET’s last offering came in late October, after which shares nearly halved in less than a month amid a broad drawdown in speculative, volatile stocks beloved by retail traders.

More Markets

See all Markets

Luke Kawa1m

Investors just made a mammoth $133 billion flip from cash to stocks, per Goldman Sachs

It’s a dash from cash, with investors taking billions in dry powder and pouring that money into the stock market.

“We saw strong net flows into global equity funds last week, led by stronger inflows into US and EM equity funds (+$71 billion vs $2 billion in the previous week) — more than 35x-ed the flows,” wrote Goldman Sachs’ Gail Hafif, Brian Garrett, and Lee Coppersmith. “While equity flows increase, money market fund assets fell by $62 billion. This is the 3rd largest level in our dataset (!).”

The trio is bullish on US stocks, seeing “the case for contained selloffs coupled with relief rallies as the most likely path forward in the near term.”

Luke Kawa

11m

Retail traders’ monthly appetite for stocks ascends to fresh record

“The current ‘new year’ momentum has been sustained and has now pushed retail activity to an all-time high on a rolling monthly basis,” according to JPMorgan.

BRITAIN-LONDON-FIREWORKS-NEW YEAR-CELEBRATION

J. Edward Moreno35m

Moderna extends rally on positive cancer vaccine results

Moderna has more than doubled since it announced on Tuesday that its cancer vaccine reduced the risk of relapse or death for melanoma patients.

The five-year data from a Phase 2b trial showed that Moderna’s vaccine, when used with Merck’s blockbuster treatment Keytruda, reduced the risk of recurrence or death by 49% compared with Keytruda alone. The news gave investors hope that Moderna, which is best known for quickly developing a COVID-19 vaccine, may soon have another lucrative product in its portfolio.

Last week, Moderna said it expects to report total 2025 revenue of $1.9 billion, on the high end of its latest guidance of between $1.6 billion and $2 billion, amid better-than-expected vaccination rates. As demand for the COVID-19 vaccine, its sole revenue-generating product, has tanked, the company has aggressively cut costs and focused on expanding its portfolio.

The combination of positive announcements early in the year has made Moderna the second-best performer in the S&P 500 Index in 2026, behind newfound AI darling Sandisk.

Luke Kawa3h

Oracle gains amid report that the TikTok deal is poised to close this week

Oracle is gaining in premarket trading as Semafor reports that China and the US have signed off on the sale of TikTok’s US operations to a consortium in which the software giant is one of the three leading investors.

The transaction is poised to close this week, per the report, citing people familiar with the situation.

In mid-December, Oracle booked a huge gain after the CEO of TikTok owner ByteDance indicated that he’d signed contracts with Oracle and the other major investors leading this consortium, private equity firm Silver Lake and Abu Dhabi-backed tech investment company MGX.

If, as previous reporting suggested, the transaction values TikTok’s US operations at about $14 billion, that would mark a fairly low price tag for a lot of eyeballs and ad dollars. This pact will also afford Oracle’s cloud business an opportunity to deepen its preexisting relationship with TikTok.

J. Edward Moreno3h

Abbott slumps after reporting sales miss, disappointing Q1 guidance

Abbott Laboratories fell in premarket trading after it reported fourth-quarter sales that missed Wall Street estimates and gave disappointing guidance for the current quarter.

The company said it expects to report first-quarter adjusted earnings per share of between $1.12 and $1.18, below the $1.20 analysts polled by FactSet were expecting. For the full year, it expects to report adjusted earnings per share of $5.55 to $5.80, in line with the $5.67 the Street is penciling in.

Abbott also reported $11.5 billion in sales for the fourth quarter, less than the analyst consensus of $11.8 billion. The sales miss was driven by lower-than-expected sales of its medical devices, its largest segment. Its profits for the quarter hit $1.50 per share, right in line with expectations.

The stock fell more than 5% in premarket trading on Thursday.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.